Preclinical research in Rett syndrome: Setting the foundation for translational success. by Katz, Dm et al.
Introduction
Rett syndrome (RTT) is a prototype childhood neurological disease
characterized by features that are observed in many other disorders
ranging from autism to Parkinson’s disease and dystonia. The disorder
affects ~1 in 10,000 females and is most often caused by mutations in
the gene encoding methyl-CpG-binding protein 2 (MeCP2), a
transcriptional regulatory protein. It has been shown that many of the
features of RTT are reversible in mice (Gadalla et al., 2011; Guy et al.,
2007), and that these features are probably due to dysfunction of neurons
and supporting cells, rather than neural degeneration (Armstrong, 2002).
These findings provide hope that some and perhaps most symptoms
can be reversed in affected individuals if we discover effective
therapies that can overcome the consequences of loss of function or
dysfunction of MeCP2.
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In September of 2011, the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD), the International Rett Syndrome Foundation (IRSF)
and the Rett Syndrome Research Trust (RSRT) convened a workshop involving a broad cross-section of basic scientists,
clinicians and representatives from the National Institutes of Health (NIH), the US Food and Drug Administration (FDA),
the pharmaceutical industry and private foundations to assess the state of the art in animal studies of Rett syndrome
(RTT). The aim of the workshop was to identify crucial knowledge gaps and to suggest scientific priorities and best practices
for the use of animal models in preclinical evaluation of potential new RTT therapeutics. This review summarizes outcomes
from the workshop and extensive follow-up discussions among participants, and includes: (1) a comprehensive summary
of the physiological and behavioral phenotypes of RTT mouse models to date, and areas in which further phenotypic
analyses are required to enhance the utility of these models for translational studies; (2) discussion of the impact of genetic
differences among mouse models, and methodological differences among laboratories, on the expression and analysis,
respectively, of phenotypic traits; and (3) definitions of the standards that the community of RTT researchers can implement
for rigorous preclinical study design and transparent reporting to ensure that decisions to initiate costly clinical trials are















    




There is a crucial need to develop effective treatments for RTT.
Encouragingly, several key findings suggest that RTT could be
treatable in humans, and might be a promising model for developing
rigorous paradigms for evaluating therapeutic interventions not only
in RTT but in other postnatal childhood disorders as well. First, RTT
typically manifests months after birth, arguing that key embryonic and
perinatal developmental steps take place normally in affected
individuals. Second, there are several excellent mouse models in which
many of the somatic, behavioral and physiological changes observed
in individuals with RTT are reproduced (discussed in detail below).
Third, the findings that some RTT-like symptoms are reversible in
mouse models following reactivation of silent Mecp2 alleles (Guy et
al., 2007; Lioy et al., 2011; Robinson et al., 2012) or transgene-mediated
Mecp2 replacement (Alvarez-Saavedra et al., 2007; Collins et al., 2004;
Giacometti et al., 2007; Jugloff et al., 2008; Luikenhuis et al., 2004), and
that most RTT-like symptoms are reproduced following loss of
MeCP2 in adult animals (Cheval et al., 2012; McGraw et al., 2011;
Nguyen et al., 2012), argue that most of the disease phenotypes are
caused by functional disturbances of neural circuits, rather than
irreversible developmental brain abnormalities. Thus, the challenge
for the field now is to build on these exciting findings by identifying
therapeutic opportunities, testing them rigorously in RTT models to
determine their effectiveness in improving clinically relevant outcome
measures, and establishing their safety with chronic use.
Given the emergence of new therapeutic leads in the field (cf. Abdala
et al., 2010; De Filippis et al., 2012; Deogracias et al., 2012; Kron et al.,
2012; McCauley et al., 2011; Nag and Berger-Sweeney, 2007; Ogier et
al., 2007; Roux et al., 2007; Schmid et al., 2012; Tropea et al., 2009; Zanella
et al., 2008), RTT models hold great promise for translational research,
particularly for prioritizing and validating potential treatment strategies
prior to launching costly clinical trials. Unfortunately, as discussed later
in this review, there is a long history of failure in translating promising
findings from preclinical animal models to clinical success, especially
for neurological disorders. Therefore, it is crucial that the RTT research
community develops best practices and standards for performing
preclinical trials, and identifies the best path forward for justifying the
advancement of preclinical discoveries to clinical trials. These steps are
essential to avoid involving individuals with RTT in unnecessary
clinical trials, wasting precious research money, and raising unwarranted
expectations for the patients and their families.
With these goals in mind, the National Institute of Neurological
Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National
Institute of Child Health and Human Development (NICHD), and
private United States organizations supporting RTT research [the
International Rett Syndrome Foundation (IRSF) and the Rett Syndrome
Research Trust (RSRT)] held a workshop entitled ‘Setting Priorities for
Therapy Development in Rett Syndrome’ at the Hyatt Regency
Bethesda (Bethesda, MD) on 25-27 September 2011 to discuss how
to optimize the predictive value of animal models in RTT preclinical
research and avoid the pitfalls that often lead to failure on clinical
translation. In addition to these funding agencies and foundations,
workshop participants included members of the RTT research
community and the pharmaceutical industry, clinicians, and
representatives from the US Food and Drug Administration (FDA).
The workshop agenda and participant list are available in supplementary
material Tables S1 and S2, respectively.
A key component of the workshop was the creation of working groups
that were responsible for reviewing the state of the art in phenotypic
analyses of mouse models of RTT. Four groups were created, each focusing
on different phenotypic domains: (1) general health, locomotion and
lifespan (led by Dr James Eubanks, University of Toronto); (2) respiratory
and autonomic control (led by Drs David Katz, Case Western Reserve
University School of Medicine, and Jeffrey Neul, Baylor College of
Medicine); (3) cognitive, social and anxiety phenotypes (led by Dr Joanne
Berger-Sweeney, Tufts University); and (4) cellular and synaptic
phenotypes (led by Dr Lucas Pozzo-Miller, The University of Alabama
at Birmingham). Reporting on key outcomes from the workshop, as well
as subsequent discussions among the working groups, this paper
reviews the phenotypic characteristics of currently available mouse models
of RTT, highlights current knowledge gaps, and identifies criteria and
best practices for preclinical study design that we hope will optimize the
ability of the RTT research community to translate basic findings into
new therapeutic approaches. We begin with a brief overview of the
principal clinical features of RTT, which is a necessary foundation for
evaluating the degree to which existing mouse models reproduce
phenotypes of the human disease, and for identifying sensitive and
relevant outcome measures for preclinical and clinical trials.
Genetic and clinical-pathological features of RTT
Loss-of-function mutations in MECP2, an X-linked gene, account for
the vast majority (~95%) of typical RTT cases (Amir et al., 1999). Most
mutations arise spontaneously (de novo) in the paternal germ line; thus,
individuals with RTT are typically females who, owing to X-
chromosome inactivation, are somatic mosaics for normal and
mutant MECP2. Boys with mutations that cause RTT in females
typically die before or soon after birth with a severe encephalopathy
(discussed in more detail below).
RTT is distinguished by its unique time course and phenotypic
complexity. Affected individuals present with postnatal neurological
regression, usually starting between 1.5 and 3 years of age (but
sometimes as early as 6 months of age), with loss of acquired hand skills
and spoken language and, in some cases, social withdrawal or extreme
irritability that can resemble autism (Hagberg, 2002; Neul et al., 2010).
After regression, there is a stabilization of skills, rather than a relentless
progression, a feature that differentiates RTT from neurodegenerative
conditions such as Batten disease or Huntington’s disease. During this
pseudo-stationary or plateau stage, characteristic features of RTT such
as repetitive hand movements (stereotypies), which can be present before
or during regression, become more prominent. Later in life, many affected
individuals enter a stage of motor decline in which ambulation can be
lost, and Parkinsonian features such as rigidity and hypomimia become
prominent (FitzGerald et al., 1990a; FitzGerald et al., 1990b). Mutations
in other genes such as cyclin-dependent kinase like 5 (CDKL5) and
forkhead box G1 (FOXG1) can cause phenotypes overlapping with those
seen in RTT (Archer et al., 2006; Ariani et al., 2008); however, several
features, such as congenital onset and infantile spasms in CDKL5-mutant
patients, and congenital onset and hypoplasia of the corpus callosum
in FOXG1-mutant patients, distinguish these disorders from typical RTT
(Kortüm et al., 2011).
During the regression stage, some individuals with RTT develop
autistic features that include social withdrawal, avoidance of eye contact
and indifference to visual or auditory stimuli (Mount et al., 2002a; Mount
et al., 2003). After regression, some of these autistic features decrease,
and most affected individuals develop intense eye gaze that they use
for communication (Coenraads, 2007; Kaufmann et al., 2012). Recent
work has shown that features such as stereotypies and lack of
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language skills persist throughout the life of affected individuals,
although hand stereotypies can change from rapid movements to
midline hand clasping with age. Additional behavioral problems include
anxiety in response to novel situations (Mount et al., 2002b), increased
behavioral rigidity and increased pain tolerance (Downs et al., 2010).
Individuals with RTT are considered to have severe intellectual
disability; however, because affected individuals have severe
impairments in their ability to communicate, it is difficult to make
accurate assessments of their intellectual ability (Baptista et al., 2006;
Neul et al., 2010).
Movement abnormalities are a major issue in RTT (FitzGerald et
al., 1990a; FitzGerald et al., 1990b), with the most obvious being the
repetitive hand stereotypies, which seem to interfere with volitional
hand use. Gait is almost always disrupted, with evidence of ataxia and
apraxia. Dystonia is common, seen first in the ankles and eventually
progressing to many joints. Axial hypotonia is present early in the disease
course but, as children become young adults, increased tone with
features of rigidity becomes more prominent. Additional movement
abnormalities include tremor, myoclonus, chorea, facial grimacing and
severe teeth grinding. Most individuals with RTT have scoliosis, and
some require surgical intervention (Percy et al., 2010).
Nutrition and gastrointestinal function are also major clinical issues
in RTT, and there is marked growth failure in most affected individuals
(Tarquinio et al., 2012). It has long been recognized that head growth
is impaired, resulting in acquired microcephaly (Hagberg et al.,
1983), and height and weight are usually markedly diminished
(Schultz et al., 1993). However, a subset of individuals with RTT are
overweight or obese (Renieri et al., 2009), a feature that is often
associated with higher functioning and possibly improved oromotor
skills (Motil et al., 1999). Many individuals with RTT have various
gastrointestinal problems, including significant chewing and swallowing
difficulties, gastroesophageal reflux, gastrointestinal dysmotility and
severe constipation, which severely decrease the quality of life for
patients and their families (Motil et al., 2012).
Dysregulation of breathing and autonomic homeostasis are very
common in RTT. Respiratory abnormalities, which include periods of
forceful breathing (hyperventilation), severe pauses in breathing
(including breath holds) that can cause cyanosis and even loss of
consciousness, and abnormal cardiorespiratory coupling, are more
severe during wakefulness than during sleep (Elian and Rudolf, 1991;
Julu et al., 2001; Julu and Witt Engerström, 2005; Marcus et al., 1994;
Weese-Mayer et al., 2008; Weese-Mayer et al., 2006) and can be
exaggerated during periods of excitement or stress. Autonomic
abnormalities include periods of vasomotor disturbance (usually
associated with cold hands and feet), abnormal sweating, decreased
heart rate variability, evidence of sympathetic-parasympathetic
imbalance and prolongation of corrected QT interval (an indication
of abnormal cardiac electrical activity) in a subset of individuals (Guideri
et al., 2004; McCauley et al., 2011; Sekul et al., 1994). One quarter of
deaths in RTT are sudden and unexpected (Kerr et al., 1997), and might
result from complications of cardiorespiratory dysfunction.
Brain electrical activity is not typical in individuals with RTT, as shown
by the markedly disrupted pattern observed on electroencephalograms
(EEGs) (Glaze et al., 1998) and the high probability of seizures (Glaze
et al., 2010). Seizures, ranging from complex partial to generalized tonic-
clonic, are most commonly seen after other symptoms appear (usually
after age two) and correlate with the severity of the phenotype. In addition
to true epileptic events, individuals with RTT also have non-epileptic
paroxysmal events, and video EEG is needed to differentiate between
them (Glaze et al., 1998).
Despite the severity and phenotypic complexity of RTT, the brains
of individuals with RTT do not show gross neuropathological changes,
nor evidence of neuronal or glial atrophy, degeneration, gliosis, or
demyelination, indicating that RTT is not a neurodegenerative disorder
(Jellinger et al., 1988; Reiss et al., 1993). Smaller total brain volume and
smaller neurons (but with a higher cell density) have been observed in
several brain regions, including the cerebral cortex, hypothalamus and
the hippocampal formation (Bauman et al., 1995a; Bauman et al., 1995b).
The size and complexity of dendritic trees are reduced in cortical
pyramidal cells (Armstrong et al., 1995; Armstrong et al., 1998), and levels
of microtubule-associated protein-2 (MAP-2), a protein involved in
microtubule stabilization, are lower throughout the neocortex of RTT
autopsy material (Kaufmann et al., 2000; Kaufmann et al., 1995). In
addition, the density of dendritic spines is lower in pyramidal neurons
of the frontal cortex (Belichenko et al., 1994; Jellinger et al., 1988) and
in the CA1 region of the hippocampus (Chapleau et al., 2009).
Mouse models of RTT
Identification of MECP2 as the disease-causing gene led rapidly to the
development of mouse models of RTT (Table 1) that recapitulate, to
varying degrees, the underlying molecular and genetic defects and
symptoms of the human disease (Table 2). Established models
include mice carrying either global alleles (null, hypomorphic, large
deletions and point mutations) or conditional null alleles (reviewed in
Calfa et al., 2011b). As discussed below, a major focus at the workshop
concerned the utility of the various models for translational studies.
One point of consensus was that conditional alleles (i.e. cell-specific
deletions created by cross-breeding of floxed Mecp2 mice with Cre-
deleter lines), although useful for elucidating mechanisms of
neurological dysfunction, are unlikely to be of value in translational
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Table 1. Mutant Mecp2 mouse models discussed in this article 
Allele type Allele description Reference 
Null alleles 
Mecp2tm1.1Bird Exon 3-4 deletion Guy et al., 2001 
Mecp2tm1.1Jae Exon 3 deletion Chen et al., 2001 
Mecp2tm1Pplt MBD deletion Pelka et al., 2006 
Truncation mutation 
Mecp2tm1Hzo Codon 308>C-terminal 
truncation 
Shahbazian et al., 2002 
Human point mutations 
Mecp2tm1.1Coyle Knock-in stop R168X Lawson-Yuen et al., 2007 
Mecp2tm1.1Vnar Knock-in missense A140V Jentarra et al., 2010 
Mecp2tm1.1Hup Knock-in stop R168X Brendel et al., 2011 
Mecp2tm1.1Joez Knock-in missense T158A Goffin et al., 20112  




Mecp2tm1Bird Hypomorphic Mecp2 allele Guy et al., 2001 
Mecp2tm2Bird Stop upstream of exon 3 Guy et al., 2007 
Mecp2tm1.1Meg  Knock-in missense S421A  Cohen et al., 2011 
The alleles listed above have all been published or submitted to the MGI database. 















    




studies because, by design, they do not recapitulate the global loss of
MeCP2 that is characteristic of RTT.
Global Mecp2 alleles generally fall into three categories: (1) null
mutations (Mecp2tm1.1Bird, Mecp2tm1.1Jae or Mecp2tm1Pplt) (Chen et al.,
2001; Guy et al., 2001; Pelka et al., 2006), which are similar to the large
deletions found in ~10% of affected people; (2) truncations and single-
nucleotide mutations that approximate or reproduce mutations
found in individuals with RTT (codon 308-C-terminal truncation:
Mecp2tm1Hzo; R168X: Mecp2tm1.1Coyle and Mecp2tm1Hup; T158A:
Mecp2tm1.1Joez; and R255X: Mecp2tm1.1Irsf) (Brendel et al., 2011; Goffin
et al., 2012; Jentarra et al., 2010; Lawson-Yuen et al., 2007; Shahbazian
et al., 2002); and (3) point mutations that either model related
neurodevelopmental disorders [A140V: Mecp2tm1.1Vnar (Jentarra et al.,
2010)] or provide mechanistic insight into MeCP2 function [S421A:
Mecp2tm1.1Meg (Cohen et al., 2011)]. Mutant mice that are hypomorphic
for Mecp2 (Mecp2tm1Bird) (Kerr et al., 2008; Samaco et al., 2008) have
also been created; these animals express MeCP2 at ~50% of wild-type
levels due to retention of a selectable marker cassette in the floxed Mecp2
allele and, as expected, exhibit more modest behavioral impairments
compared with the complete nulls. Phenotypic details of the various
RTT mouse models are summarized in supplementary material
Tables S3-S7.
During the workshop, discussion of mouse models focused on three
key concepts used to evaluate the utility of a model for translational
studies: (1) construct validity (similarities in underlying molecular
mechanisms in humans and mice); (2) reproducibility (findings
replicated in more than one laboratory) and robustness (effect size, and
whether or not findings are generalizable to more than one model
and/or experimental condition); and (3) face validity (similarities in
anatomical, physiological and/or behavioral phenotypes in humans and
mice).
Construct validity
To some degree, all global null or hypomorphic alleles have construct
validity, given that most disease-causing mutations in human RTT cause
loss of MeCP2 function (e.g. Kudo et al., 2001). However, as noted above,
only 10% of mutations in individuals with RTT are deletions that are
large enough to approximate a true null condition. Moreover, although
male mice have, until recently, been used most frequently in preclinical
studies of RTT, male nulls and hypomorphs do not exhibit the
genetic mosaicism that is characteristic of the vast majority of
individuals with RTT, who are female. Furthermore, it is not known
whether complete loss of MeCP2 in cells (either in hemizygous males
or heterozygous females) recapitulates the effects of a point mutation
or truncated protein, including the possibility of toxic gain of function
with some of the human mutations. Thus, translational studies in mice
carrying null alleles might only be relevant to a relatively small subset
of individuals with RTT. However, many MECP2 point mutations, in
addition to large deletions, are believed to eliminate gene function; in
particular, some mutations in the methyl-binding and transcriptional
repression domains cause the most severe RTT phenotypes and might
be relevant to the null allele. Therefore, current attempts to establish
the construct validity of various RTT mouse models (e.g. null versus
point mutations) would benefit from detailed comparisons of how the
corresponding alleles, when studied in the same genetic background,
alter target gene expression, cell physiology and neurological function.
It would also be helpful to know whether the two most commonly used
null alleles, Mecp2tm1.1Bird and Mecp2tm1.1Jae, are functionally equivalent,
given that they were generated using targeting strategies directed against
slightly different sequences in the coding region of Mecp2. Ultimately,
choosing mouse models for translational studies might require
compromises between construct validity and practical concerns – i.e.
to optimize phenotypes that are robust and that develop within a
timeframe that is cost effective for large-scale preclinical studies.
dmm.biologists.org736
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Table 2. Comparison of phenotypes in RTT individuals and Mecp2-
mutant mice 
Core phenotypes in RTT 
individuals 




Neuronal hypotrophy (reduced 
neuronal soma size, smaller 
dendritic arbors and lower spine 
density) 
++ 
Respiratory and autonomic control 
Abnormal breathing (irregular 
pattern, respiratory pauses, 
increased mean frequency)  
++ 
Prolonged QTc + 
Vasomotor disturbances nd 
Gastrointestinal dysmotility nd 
Motor function 
Gait abnormalities ++ 
Stereotypies + 
Tremors ++ 
Early hypotonia nd 
Lack of purposeful hand movements ? 
(poor nest building might reflect 
decreased forepaw function) 
Parkinsonian features ? 
(mice exhibit hypokinesis; 
mechanism unknown) 
Dystonia ? 
(hindlimb clasping might be a sign 
of dystonia) 
Cognition and behavior  
Cognitive deficits ++ 
Social withdrawal +/– 
Increased anxiety +/– 
Loss of speech ? 
Repetitive behaviors ? 
(some indication of repetitive and/or 
excessive grooming) 
Other 
Reduced lifespan ++ 
EEG abnormalities and seizures ++ 
Neurological regression ++ 
Sleep cycle disturbances nd 
Scoliosis nd 
++, phenotypes similar to human and reported in more than one mouse model; +, 
phenotypes similar to human and reported in only one mouse model to date; +/–, 
conflicting data in different mouse models; ?, suggestive or inconclusive data; nd, not 
determined. Detailed mouse phenotyping data are available in online supplementary 
















    




What is notable in RTT mouse models is evidence of construct
validity beyond the genetic mutations themselves, including
neurochemical abnormalities found in individuals with RTT. For
example, diverse mouse models reproduce the reduced levels of biogenic
amines and brain-derived neurotrophic factor (BDNF) that are found
in the brains of RTT patients (Wang et al., 2006; Deng et al., 2007; Li
et al., 2012; Chang et al., 2006). Thus, removing MeCP2 function from
mice reproduces at least some of the same cell signaling deficits as
MECP2 mutations in humans.
Reproducibility and robustness
In addition to the allelic diversity of current RTT models, RTT research
is further confounded by the fact that different laboratories study
different alleles on different genetic backgrounds and at different
developmental stages, making it difficult to discern the effects of a
specific allele from genetic, environmental and maturational influences.
Expression of the same Mecp2 allele on different genetic backgrounds
can confer significant differences in phenotypic effects, including but
not limited to time of onset and symptom severity. Similarly, the degree
to which animal husbandry practices (including food, water, lighting,
noise, handling and bedding), maternal age and quality of maternal care
influence the phenotypic effects of Mecp2 alleles has not been
studied. Furthermore, disease progression across the lifespan has not
been carefully evaluated in most models, especially in heterozygous
females, as discussed below. For translational studies, therefore, the
variations in phenotype that are influenced by genetic background and
animal husbandry practices highlight the importance of validating
phenotypes and therapeutic efficacy in multiple models and in
multiple laboratories. Such validation will hopefully mitigate the
possibility that a given study is treating idiosyncratic gene-gene or gene-
environment interactions that might not generalize or be relevant to
the human disease.
Fortunately, and as would be expected based on the high penetrance
of MECP2mutations in humans, at least some phenotypes that mimic
symptoms of human RTT are common to multiple Mecp2-mutant
mouse models (see below). However, relatively little is known about
whether RTT mouse models recapitulate the unique features of
progression, regression and stabilization that define the human
disease. This might reflect the overall bias of the scientific community,
which has performed most phenotypic analyses in male hemizygous
mice. These animals might best model the small number of human male
patients who are hemizygous for mutant MECP2 and present, not with
clinically defined RTT, but with a severe encephalopathy accompanied
by a failure to acquire skills, rather than regression. An increasing
number of laboratories are shifting to phenotypic analysis of
heterozygous female mice, which might yield models that more
closely phenocopy human RTT, including temporal features such as
disease regression.
Face validity: RTT phenotypes recapitulated in mouse
models
The following sections provide an overview of the key
pathophysiological findings that have been reported in RTT mouse
models carrying global (rather than cell-specific) Mecp2 mutant
alleles. Most models exhibit a broad spectrum of phenotypes that are
similar to those seen in RTT individuals, including shortened lifespan,
motor and sensory impairments, breathing abnormalities, cognitive
and behavioral dysfunction, and cellular and synaptic defects (reviewed
in Calfa et al., 2011b) (summarized in Table 2). However, care must
be taken not to assume, on the basis of face validity alone, that similar
behavioral phenotypes in mice and humans necessarily arise from the
same underlying pathophysiological mechanisms. Emphasis here is
given to those findings that are most robust and reproducible across
different models and/or genetic backgrounds and in different
laboratories, with the goal of identifying the models and phenotypes
that will be most useful for translational studies. This overview is by
no means exhaustive; further details and additional references for each
model are provided in the accompanying online supplemental material
(supplementary material Tables S3-S7). Male mice that are hemizygous
for Mecp2 null alleles are referred to as ‘Nulls’, and females that are
heterozygous for Mecp2 null alleles are referred to as ‘Hets’.
General health, locomotion and lifespan
Gross motor dysfunction and shortened lifespan are common features
of diverse RTT mouse models on different genetic backgrounds and
broadly recapitulate the clinical presentation in individuals with RTT
(Table 2; supplementary material Table S3). Mecp2-mutant mice
exhibit robust and reproducible abnormalities in motor behaviors,
including hypoactivity (Chen et al., 2001; Guy et al., 2001; Jugloff et al.,
2008; Stearns et al., 2007), impaired balance and coordination (Alvarez-
Saavedra et al., 2007; Jugloff et al., 2008; Kondo et al., 2008; Shahbazian
et al., 2002; Stearns et al., 2007), spontaneous tremors (Alvarez-
Saavedra et al., 2007; Brendel et al., 2011; Chen et al., 2001; Goffin et al.,
2012; Guy et al., 2001; Lawson-Yuen et al., 2007; Pelka et al., 2006;
Shahbazian et al., 2002; Stearns et al., 2007), hindlimb clasping (Brendel
et al., 2011; Chen et al., 2001; Goffin et al., 2012; Guy et al., 2007; Guy
et al., 2001; Kondo et al., 2008; Lawson-Yuen et al., 2007; Pelka et al., 2006;
Stearns et al., 2007), and impaired limb and postural reflexes (Picker et
al., 2006; Santos et al., 2007). In male Nulls, these deficits occur early
(within 6 weeks of birth) and are generally more pronounced than in
female Hets; female Hets typically develop milder motor impairments
(usually not seen before 10 weeks of age) and exhibit greater phenotypic
variability (Stearns et al., 2007). In addition, excessive and repetitive
grooming has been observed in male Mecp2tm1.1Jae Nulls and might
represent a form of motor stereotypy (Stearns et al., 2007). To a first
approximation, many of these phenotypes seem to mimic motor
deficits exhibited by individuals with RTT. For example, hindlimb clasping,
although not specific to RTT mice, might represent a form of motor
dysfunction. However, further work is required to determine the
degree to which these human and mouse phenotypes truly share common
underlying neurological mechanisms.
Lifespan is severely shortened in male Nulls (including both the
commonly employed Mecp2tm1.1Bird and Mecp2tm1.1Jae models), which
rarely live longer than 3 months. Prior to death, male Nulls often exhibit
severe hypoactivity, kyphosis and disheveled fur, and typically undergo
severe weight loss. In female Hets carrying null alleles, there is a higher
than normal rate of sudden and unexpected death (unpublished
observations from multiple groups), although kyphosis and disheveled
fur are less reproducibly observed. Lifespan is also reduced in most
of the male hemizygous human (targeted) mutation models (Goffin
et al., 2012; Lawson-Yuen et al., 2007; Shahbazian et al., 2002), but the
degree varies with the specific Mecp2 allele and/or genetic background.
An exception is the Mecp2tm1.1Vnar (A140V) mutant line, which has an
apparently normal lifespan and, other than cellular abnormalities, does
not exhibit many obvious phenotypic defects (Jentarra et al., 2010); these
findings are consistent with clinical data showing that missense A140V
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mutations are usually associated with milder phenotypes in males and
have not been reported to cause classical RTT in females.
In contrast to the relatively robust phenotypes described above,
genetic background seems to have a significant impact on body weight.
Mecp2 null alleles on a C57BL/6 background tend to have reduced body
weight (Guy et al., 2001; Pelka et al., 2006; Stearns et al., 2007; Ward
et al., 2011), whereas alleles on the 129 background often exhibit
increased body weight (Chen et al., 2001; Shahbazian et al., 2002).
Lonetti and colleagues used a mixed genetic background (B6.129SF1)
and found no evidence of increased body weight (Lonetti et al., 2010).
Respiratory and autonomic phenotypes
The most robust breathing phenotype in RTT mouse models that has
been reproducibly observed by different laboratories and in different
mouse strains is abnormal variation in respiratory cycle length in room
air, including respiratory pauses and periods of tachypnea associated
with decreased expiratory time and increased mean breathing
frequency (Table 2; supplementary material Table S4). These breathing
abnormalities closely phenocopy respiratory dysfunction observed in
individuals with RTT. Respiratory pauses occur in male Nulls, and
female Hets and hypomorphs, with an earlier onset in Nulls (by ~5
weeks) compared with Hets (~10 weeks). Null males and Het females
also exhibit exaggerated respiratory reflexes, including enhanced vagally
induced respiratory pauses and increased hypoxic ventilatory responses
(Bissonnette and Knopp, 2006; Johnson et al., 2012; Roux et al., 2008;
Stettner et al., 2007; Voituron et al., 2009).
Although cardiac phenotypes have been less well characterized,
recent work indicates that male Nulls and female Hets exhibit
prolongation of the corrected QT interval and an increased susceptibility
to induced cardiac arrhythmia and cardiac death. This seems to be a
progressive phenotype as female Hets exhibit these phenotypes at 11
but not 4 months of age (McCauley et al., 2011).
Cognitive, social and anxiety phenotypes
As noted above, the severity of communication deficits in individuals
with RTT has hampered systematic evaluation of their cognitive abilities.
Thus, although cognitive deficits have been identified in RTT mouse
models (Table 2; supplementary material Table S5), the face validity
of these findings has been difficult to establish. One of the most reliable
and robust cognitive phenotypes in RTT mice – i.e. replicated by
different laboratories, in different RTT mouse models with diverse
Mecp2 alleles and/or genetic backgrounds – is impairment in
contextual fear conditioning, which is a test of associative learning and
memory. This phenotype is apparent in male Nulls by about 6 weeks
of age (Stearns et al., 2007); similarly, the human mutation models tested
to date – male Mecp2tm1.1Joez and Mecp2tm1Hzo mice – show impairments
in contextual fear conditioning by 10 and 20 weeks of age, respectively
(Shahbazian et al., 2002; Moretti et al., 2006; Goffin et al., 2012). Object
recognition testing has also revealed learning deficits in Mecp2tm1.1Jae
male Nulls and female Hets (Schaevitz et al., 2010; Stearns et al., 2007)
and Mecp2tm1.1Meg knock-in mice (Cohen et al., 2011), the models tested
thus far. Likewise, motor-cerebellar learning is impaired in all Mecp2
models examined to date (Goffin et al., 2012; Lonetti et al., 2010; Pelka
et al., 2006). In one study, female Mecp2tm1.1Jae Hets were found to have
milder, more variable cognitive impairments as adults (Stearns et al.,
2007), and more recent evidence indicates that behavioral phenotypes,
including cognitive impairments, are detectable in young Mecp2tm1.1Bird
Hets (Samaco et al., 2012).
In contrast to the robust cognitive phenotypes, social behavior
phenotypes in RTT mouse models vary widely, depending on the Mecp2
allele and genetic background. Comparison among models is further
complicated by methodological differences in social testing paradigms
used in different studies. Nonetheless, all models tested thus far show
a preference for spending time with another mouse rather than an
inanimate object, unlike some models of other autism spectrum
disorders that show no preference, such as BTBR mice (McFarlane et
al., 2008). However, the extent and even nature of sociability differs
across models, depending on the allele and/or genetic background. For
example, male Mecp2tm1.1Jae and Mecp2tm1.1Bird mice show evidence of
increased sociability, including increased time at partitions and more
time exploring unfamiliar mice (Kerr et al., 2008; Schaevitz et al., 2010).
Similarly, male Mecp2tm1Hzo mice on a C57BL/6J background exhibit
enhanced pro-social behavior compared with wild-type mice (Pearson
et al., 2012). In contrast, the same allele (male Mecp2tm1Hzo) on a
129/SvEv or mixed 129SvEv:B6 background exhibits reduced social
interactions as demonstrated in male resident-intruder and partition
tests (Moretti et al., 2005; Moretti et al., 2006; Shahbazian et al., 2002).
Thus, the impact of reduced MeCP2 function per se on social
behavior remains very unclear, as is the relevance of the mouse
phenotypes identified thus far to the social withdrawal and autistic
features seen in some individuals with RTT.
Likewise, measures of anxiety vary widely depending on allele, genetic
background and testing paradigm. Using the elevated plus and zero
mazes, male Nulls and Mecp2tm1.1Joez mutants seem less anxious than
wild types (i.e. they spend more time in light spaces of the maze) (Goffin
et al., 2012; Kerr et al., 2012; Pelka et al., 2006; Stearns et al., 2007). The
findings are the opposite in male Mecp2tm1Hzo mutants, which are more
anxious in the same tasks (De Filippis et al., 2010; McGill et al., 2006).
Using the open field, where mice ambulate between the center of the
circular field (less anxious behavior) and the periphery of the field (more
anxious behavior), male Mecp2tm1Hzo mutants and female Mecp2tm1.1Jae
Hets seem more anxious than wild types (De Filippis et al., 2010; Lonetti
et al., 2010).
A few laboratories have demonstrated that RTT mice exhibit
abnormal ultrasonic vocalizations when pups are separated from their
mothers during early postnatal development. Specifically, beginning
at postnatal days 4-6, neonatal ultrasonic vocalizations are altered,
although in opposite directions in the two Mecp2models tested to date:
vocalizations are decreased in male Mecp2tm1Hzo mice and increased
in both male Null and female Het Mecp2tm1.1Jae mice compared with
wild-type littermates (De Filippis et al., 2010; Picker et al., 2006).
Whether these apparently conflicting results reflect true strain
differences remains to be determined. Furthermore, although many
individuals with RTT lack speech, most are very vocal. A better
understanding of the underlying neural circuit dysfunction might help
to differentiate between the preservation of vocalization and the loss
of speech in RTT. Clearly, this is an important area for further
investigation, because loss of acquired speech is a hallmark of classical
RTT, and identifying a robust mouse model for this feature would be
a valuable tool for understanding the underlying pathophysiology and
for future translational studies.
Importantly, many behavioral tasks, including all of the anxiety
measures, require an animal to ambulate. Therefore, testing of
behavioral outcomes is often confounded by the severe motor
impairments that are characteristic of most RTT mouse models.
Furthermore, anxiety measures are highly sensitive (more so than for
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most behavioral tasks) to prior handling, the order of testing and the
laboratory environment. Thus, for behavioral tasks in general, and
anxiety measures in particular, it is important to control carefully for
these variables.
Cellular, synaptic and circuit phenotypes
To some degree, the reproducibility and robustness of cellular and
synaptic phenotypes in different Mecp2-mutant mice is difficult to
evaluate owing to the methodological differences between studies
published from different laboratories, and because not all available
mouse models have been systematically analyzed. However, the
prototypical features of human RTT neuropathology – such as
smaller neurons, higher neuronal packing density, reduced dendritic
arbors and abnormal dendritic spines – have all been found in
models analyzed thus far (Table 2; supplementary material Table S6).
In addition, studies of different strains of MeCP2-deficient mice have
revealed consistent impairments in one or more physiological
properties at the cellular and synaptic level in all brain regions
studied so far (supplementary material Table S6). These impairments
include network hyperexcitability in the brainstem and hippocampus
(Calfa et al., 2011a; Kline et al., 2010; Kron et al., 2012; Medrihan et
al., 2008; Zhang et al., 2008), network hypoexcitability and synaptic
hypoconnectivity in the cerebral cortex (Dani et al., 2005; Dani and
Nelson, 2009), altered intrinsic neuronal electrical properties in the
locus ceruleus and substantia nigra (Gantz et al., 2011; Taneja et al.,
2009), and dysregulation of transmitter release in cultured hippocampal
neurons and chromaffin cells (Nelson et al., 2006; Wang et al., 2006).
However, these physiological impairments exhibit significant regional
specificity: decreased excitatory synaptic drive is found in cortical
circuits, whereas increased neuronal or synaptic excitability is found
in the hippocampus and multiple brainstem regions involved in
autonomic control (reviewed in Shepherd and Katz, 2011) (see also Kron
et al., 2012). Modest impairments in individual elements (e.g.
GABAergic synapses) might lead to different outcomes depending on
the spatiotemporal construction and connectivity of the specific
neuronal network. In addition, because most physiological studies at
the cellular and synaptic level have been carried out in male Nulls, it
has rarely been feasible to distinguish primary cell-autonomous
deficits from the secondary or compensatory changes that occur in
females with a mosaic pattern of neuronal and glial Mecp2 deficiency
[see, however, Taneja et al. (Taneja et al., 2009)].
Several laboratories have documented impairments in long-term
potentiation (LTP) and depression (LTD), which are two forms of
synaptic plasticity associated with learning and memory, in brain slice
preparations from Mecp2 mutants, including Mecp2tm1.1Jae,
Mecp2tm1.1Bird and Mecp2tm1Hzo Null mice (reviewed in Boggio et al.,
2010). Reduced LTP has been found at excitatory CA3-to-CA1
synapses in the hippocampus (Asaka et al., 2006) and in layer II/III of
the primary somatosensory cortex (Lonetti et al., 2010). Reduced LTD
has been demonstrated in area CA1 (Asaka et al., 2006; Moretti et al.,
2006). So far, most studies of synaptic plasticity have analyzed
populations of neurons and synapses using extracellular electrodes.
Importantly, analysis of monosynaptic connections between pyramidal
neurons in layer V of the primary somatosensory cortex of Mecp2tm1.1Jae
Null mice using intracellular electrodes demonstrated that LTP was
intact at these synapses, provided that sufficient postsynaptic
depolarization was achieved by step depolarization or by evoked action
potentials during the induction of spike-timing-dependent plasticity
(Dani and Nelson, 2009). Thus, it is not yet clear whether LTP
phenotypes that are identified using extracellular electrodes actually
reflect weak and sparse connections rather than specific deficits in
classical mechanisms of LTP generation.
The presentation of seizure-like behaviors and atypical EEGs in RTT
individuals [i.e. focal, multifocal and generalized epileptiform
abnormalities, with rhythmic slow theta activity in the frontal-central
regions (Glaze, 2005)] is recapitulated in Mecp2-mutant mice as a
constellation of EEG abnormalities, with or without associated
seizure-like behaviors. Indeed, abnormal EEGs have been described
in male Null and female Het Mecp2tm1.1Bird mice (D’Cruz et al., 2010;
Goffin et al., 2012; Liao et al., 2012; Wither et al., 2012), as well as in
Mecp2tm1Hzo Null mice (Shahbazian et al., 2002) and Mecp2tm1.1Joez
mutants (Goffin et al., 2012).
Improving the quality and rigor of preclinical research
in RTT: a necessary step to achieving translational
success
In addition to the importance of establishing well-characterized and
validated animal models, the workshop participants discussed the need
to improve the quality and rigor of preclinical studies as an important
step in enhancing the predictive value of RTT translational research.
Barriers to translational success, regardless of the disease in question,
often include a lack of rigorous standards and transparency in
reporting preclinical studies, as well as publication bias caused by the
under-reporting of negative results in the scientific literature. At the
workshop, Dr Shai Silberberg (NINDS) reviewed recently published
meta-analyses showing that unintended biases in animal studies tend
to substantially inflate effect sizes, or lead to Type 1 errors (false
positives) and overestimations of potential therapeutic efficacy. These
unintended biases include the lack of allocation concealment [i.e. the
investigators have no knowledge of the experimental group to which
an animal belongs (Fisher et al., 2009)], blinded assessment of
outcome and random allocation of subjects to experimental groups
(see Bebarta et al., 2003; Macleod et al., 2005; Ransohoff and Gourlay,
2010; Sena et al., 2007; Landis et al., 2012). Furthermore, in recent efforts
to reproduce original findings of potential drug targets in animal models
of amyotrophic lateral sclerosis (ALS) (Scott et al., 2008), women’s health
and cardiovascular disease (Prinz et al., 2011), cancer (Begley and Ellis,
2012; Prinz et al., 2011) or spinal cord injury (Steward et al., 2012), the
authors of follow-up studies were unable to replicate most data
published by others, including those published in high-profile
journals. This failure to replicate has been attributed to a number of
factors, including chance observations due to small sample size,
concerns about study quality and transparency in reporting, lack of
robustness or generalization of the original findings, and publication
bias [see Brunner et al. for a discussion of statistical ramifications
associated with publication bias (Brunner et al., 2012)]. These and other
alarming data have prompted a number of disease-focused groups,
including the NINDS, to publish guidelines and policy statements for
improving the quality and transparency of preclinical animal research
(see Box 1).
Moreover, the NINDS considers independent replication to be 
an asset in evaluating the readiness of a candidate therapy for 
NINDS-supported translational programs or clinical trials 
(NINDS Notice NOT-NS-023; http://www.ninds.nih.gov/funding/
transparency_in_reporting_guidance.pdf). Ideally, replication should
be conducted by an independent laboratory (or by a contract research
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organization) with no financial, scientific or other vested interest in
the original study. Steward et al. discuss some of the challenges in
carrying out independent replication studies (Steward et al., 2012). For
example, exact replication of original findings can be difficult or
impossible owing to subtle differences in experimental procedures
between laboratories (such as different animal suppliers, genetic drift,
animal housing and handling, different lots of reagents, variations in
surgical or experimental procedures, etc.). In some cases, exact
replication might be necessary to validate the original findings and
evaluate their statistical significance. However, models that minimize
variability might not accurately reflect the heterogeneity of patients
in the clinical setting. Instead, replications that introduce some
variation in the procedures (e.g. testing in more than one model or strain,
as discussed below) will also test the robustness and generalization of
the outcomes and might better serve the goal of validating candidate
therapeutics (Steward et al., 2012).
Despite the challenges and many disappointing attempts to translate
positive results from animal models into effective human therapies,
there are also some notable successes. Among these is the recent finding
that arbaclofen (STX209) might reduce behavioral dysfunction in
individuals with Fragile X syndrome (Berry-Kravis et al., 2012). This
randomized, controlled Phase 2 clinical trial was initiated on the basis
of evidence that the drug reverses disease pathologies in Fmr1
mutant mice, a model of Fragile X syndrome (Henderson et al., 2012),
as well as findings from previous work in a Drosophila model of the
disease (Chang et al., 2008). As with RTT, mouse models of Fragile X
syndrome have good construct validity, and exhibit several robust and
reproducible phenotypes that can serve as a foundation for preclinical
testing. Similarly, the therapeutic efficacy of several drugs now used
for the treatment of epilepsy, including lacosamide and retigabine, was
first established in animal studies organized under the auspices of the
Anticonvulsant Screening Program at NINDS (Choi et al., 1996; Rostock
et al., 1996; Stöhr et al., 2007). This program incorporates a battery of
standardized, rigorously implemented in vivo rodent assays to screen
candidate anticonvulsant compounds for epilepsy. Importantly, these
examples provide clear evidence that preclinical models have the
potential to predict clinical efficacy in humans, provided that the models
are robust, studies are well designed and that preclinical outcome
measures are relevant to the desired clinical end points.
Summary of knowledge gaps and workshop
recommendations
Despite considerable progress in describing the pathophysiological
consequences of Mecp2 mutations in mice, crucial gaps remain that
must be addressed in order to establish optimal models for preclinical
evaluation of potential RTT therapeutics. The workshop participants
concluded that addressing the following research goals in RTT would
substantially improve the potential for translating promising preclinical
findings into clinical success; these include the need to:
• obtain a thorough understanding of the effects of genetic background
on the phenotypic consequences of different Mecp2 alleles
• generate and characterize Mecp2 alleles that model all of the most
common human RTT mutations
• develop a detailed characterization of female Hets carrying different
Mecp2 alleles (cf. Samaco et al., 2012), including how phenotypes
appear and evolve across the lifespan; such assessments are crucial
given the progressive nature of RTT and the fact that symptoms
develop (and change) over the span of years or decades in humans
• better characterize behavioral phenotypes in Mecp2 mutants,
particularly those that are relevant to RTT clinical features (e.g.
measures of cognitive function, social interactions, communication,
anxiety); develop behavioral assays that are not confounded by motor
defects
• characterize in more detail the phenotypes that represent significant
challenges for medical management of individuals with RTT,
including seizures, and gastrointestinal, cardiorespiratory, sensory
and sleep-wake problems
• develop more sensitive, reliable and relevant preclinical outcome
measures that align with clinical end points and can better predict
success in RTT clinical trials; in some cases, this will require a better
understanding of whether RTT mouse phenotypes, despite having
apparent face validity, share common underlying circuits and
neuropathological mechanisms with respective clinical phenotypes
• develop in vivo measures of target engagement (e.g. molecular
biomarkers of desired ligand-receptor activity or downstream
signaling responses), and biomarkers of disease progression and
amelioration that, ideally, are non-invasive, to facilitate translation
to clinical studies
• obtain a better understanding of the therapeutic window in RTT –
i.e. the optimal timing and duration of treatment in RTT models.
There was agreement at the workshop that outcome measures for
preclinical testing in RTT models should involve phenotypes that are
robust and reproducible, and ideally possess good construct and face
validity with corresponding RTT disease phenotypes in humans.
Although mouse phenotypes have been identified that meet these
dmm.biologists.org740
Translational research in Rett syndrome
Box 1. A call for increased rigor and transparent
reporting in preclinical research
Given the remarkably low success rate in translating preclinical research into
clinical success, a number of disease-focused groups, including the NINDS, are
recognizing the urgent need to raise the standards of preclinical studies to
encompass the rigor and transparency that is already expected of human
clinical trials [see CONSORT 2010 statement (Schulz et al., 2010)]. Recently
published guidelines and policy statements from these groups outline some
of the principles and standards of good study design and reporting when
conducting preclinical trials of candidate therapeutics – e.g. allocation
concealment, blinded assessment of outcome, random allocation of 
subjects to experimental groups and other methods designed to minimize
bias and Type 1 (‘false positive’) errors [ARRIVE Guidelines, 2010
(http://www.nc3rs.org.uk/page.asp?id1357); STAIR preclinical
recommendations (Fisher et al., 2009); NINDS Notice NOT-NS-11-023
(http://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf); 
Alzheimer’s disease preclinical research guidelines (Shineman et al., 2011)]. In
addition to publishing guidance (NINDS Notice NOT-NS-11-023), the NINDS
has incorporated these guidelines into enhanced review considerations for
NINDS-supported translational (e.g. http://grants.nih.gov/grants/guide/
pa-files/PAR-11-294.html) and clinical (e.g. http://grants.nih.gov/grants/
guide/pa-files/PAR-11-343.html) research programs. Moreover, the NINDS
convened a 2-day workshop (20-21 June 2012 in Washington, DC) entitled
‘Optimizing the Predictive Value of Preclinical Research’ to identify the key
causes of deficiencies in preclinical studies and provide recommendations 
for addressing them; the outcomes of this workshop have been reported
(Landis et al., 2012) and the workshop agenda can be accessed online
(http://www.ninds.nih.gov/funding/areas/channels_synapses_and_circuits/rig
or_and_transparency/index.htm). By raising standards and awareness, these
initiatives strive to increase the reliability, reproducibility and predictive value
















    




criteria (Table 2; supplementary material Tables S3-S7), some
phenotypic domains, particularly those involving complex behaviors
(e.g. social behaviors and anxiety), still lack consistent, reliable
readouts in current RTT models. This prompts an important question:
will amelioration of less complex behavioral phenotypes, or even cellular
and molecular defects, in preclinical trials be sufficient to predict success
in clinical trials involving more complex behavioral end points? This
is a possibility, as supported by the recent Phase 2 clinical trial mentioned
above involving Fragile X syndrome patients (Berry-Kravis et al., 2012).
This study reported improvements in social functioning following
treatment with arbaclofen, even though the preclinical data supporting
this trial consisted largely of positive drug effects on synaptic and
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Table 3. Best-practice guidelines for preclinical animal trials testing therapeutic compounds in RTT 
Parameter Recommendations 
Study design  
Sample size Because many studies are frequently underpowered, sample size calculations, based on expected variance and 
effect size, should be performed before the animal trial starts (i.e. mice should not be added during the trial, 
once data analysis has begun, in an attempt to increase statistical significance). For most RTT trials, sample sizes 
should include at least 12-16 mice per group 
Dose-response data In addition to the optimal dose, the minimally effective and maximally tolerated dose should be determined. Early 
evidence that the drug reaches the tissue target (including drug concentration at the target) and preliminary 
safety and tolerability data can help to support continued development of the candidate therapeutic (e.g. more 
comprehensive preclinical pharmacokinetics/pharmacodynamics studies) 
Timing and duration of treatment Treatment onset (e.g. in presymptomatic vs symptomatic mice) and duration (acute vs chronic) should correspond 
as closely as possible to the expected clinical trial indication. For example, in early Phase 2 RTT clinical trials, the 
intervention will probably start in individuals who are already symptomatic and will involve chronic 
intervention. In addition, data on the therapeutic window (e.g. whether the treatment is more effective when 
initiated in presymptomatic mice) and acute vs chronic treatment effects can be informative in interpreting 
clinical efficacy data and/or planning later-phase clinical trials 
Outcome measures Assessing multiple outcome measures can be informative, especially in exploratory studies. However, for the 
preclinical animal trial, primary and secondary outcome measures and/or end points should be established in 
advance, and incorporated into the statistical design of the study. The selection of outcome measure(s) should 
be as relevant to the expected clinical measure(s) as possible 
Biomarkers If available, biomarkers that measure target engagement or activity, and disease progression or amelioration, can 
be informative in animal studies, especially if the biomarker is translatable to human studies 
Statistics and minimizing bias  
Statistical design Statistical methods should be chosen before the study has begun. Once the outcome variability has been 
characterized, it is a good idea to consult with a statistician on the design of the trial 
Randomization and balancing The study design should include how mice will be randomly allocated to treatment groups (e.g. computer-
generated randomization schedules). Picking animals ‘at random’ from a cage is likely to introduce bias based on 
subtle (or not so subtle) characteristics of the animal. Treatment groups should be balanced by age and sex of 
mice, if relevant, and to prevent over-representation of sibs in any experimental cohort 
Blinding Wherever possible, individuals conducting the experiments and those analyzing the results should be blinded to 
the experimental group (i.e. allocation concealment and blinded assessment of outcome, respectively) 
Inclusion/exclusion criteria Determine in advance the criteria by which animals will be included or excluded from the study, or discarded from 
analysis (e.g. based on phenotype, disease severity, sickness or other factors that could skew the outcomes). 
Post-hoc exclusion of animals or data after the analysis (before unblinding) should be justified and reported 
Reporting  
ARRIVE guidelines We suggest consulting the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to report RTT 
preclinical animal trial results, and to include details on mouse model and genetic background, animal housing 
and handling, sample size calculations and statistical methods, methods to minimize bias (randomization, 
blinding), inclusion/exclusion criteria, animals and data excluded from analysis, and other relevant items on the 
checklist provided in the ARRIVE guidelines 
Negative results Publish all results (positive and negative outcomes) to avoid publication bias 
Conflict of interest Report any relationship that could be perceived as a conflict of interest, or that could potentially bias the study 
outcomes 
Replication  
Multiple RTT models To evaluate the robustness and generality of the original findings, we suggest validating promising treatment 
outcomes in more than one RTT mouse model/strain (e.g. comparing the Mecp2 null and a disease-specific 
mutation, mice with different genetic backgrounds, etc.). Moreover, validating findings in female heterozygous 
Mecp2 mice is imperative 
Independent replication Ideally, an independent laboratory (or a contract research organization) with no financial, scientific or other vested 
interest in the original study should conduct the replication study. The replication study can attempt to 
duplicate exactly the original experimental design or modify the procedures (e.g. using a different RTT mouse 
















    




neuronal phenotypes in Fmr1 mutant mice (Henderson et al., 2012).
Hopefully, as the RTT field moves into clinical testing of therapeutic
leads, we can validate and refine the predictive potential of the models
by comparing outcomes in mice with results obtained from human
clinical trials.
To assess the reproducibility and robustness of promising preclinical
interventions, the workshop participants recommended independent
replication of the original findings and validation in more than one RTT
mouse model or strain prior to launching later-stage translational or
clinical projects. In addition, if the original studies were performed in
male Nulls, it will be vital to replicate the findings in female Hets
whenever feasible, because these models have better construct and face
validity for RTT, as discussed above. Adopting standardized assays, tests
and outcome measures in animal studies has also been debated in the
field (Paylor, 2009; van der Staay and Steckler, 2002). At the workshop,
there was agreement that standardized testing procedures can be
valuable, especially for phenotypic characterizations (to allow head-
to-head comparisons of a phenotype across mouse models or strains,
for example); however, overly rigid adherence to ‘accepted’ standards
could ultimately inhibit the development or adoption of more
sensitive and reliable measures. The workshop participants
recommended adopting standardized testing procedures and data
analysis protocols whenever possible so that results can be meaningfully
compared across different interventions and among different
laboratories; modifications and/or improvements to standardized
protocols should be justified.
The workshop participants recognized that research consortia,
perhaps organized around specific themes (e.g. cognitive function,
respiratory control, etc.) could be a valuable tool for generating
standardized testing protocols, developing or improving preclinical
outcome measures and cross-validating preclinical trial results using
best practices for study design (described above). Support for such
activities could potentially fall within the scope of the current NIH
funding initiative PAR-11-038 (http://grants.nih.gov/grants/guide/pa-
files/PAR-11-038.html). The participants also felt that consideration
should be given to evaluating the potential value and cost effectiveness
of centralized core facilities for preclinical trials, and for validating results
from other laboratories.
Finally, we need to bring the rigor and quality of study design that
is expected of human clinical trials [see CONSORT 2010 statement
(Schulz et al., 2010)] to animal trials that test candidate therapeutics.
This will require a commitment among RTT researchers to fully disclose
all aspects of study design in their publications, including (but not
limited to) allocation concealment, blinded assessment of outcome,
random allocation of subjects to experimental groups, experimental
group sizes, breeding strategies and statistical methods. Table 3 outlines
best-practice guidelines for animal trials in RTT that were derived 
from the workshop recommendations, and adapted from the 
STAIR (Fisher et al., 2009), ARRIVE (http://www.nc3rs.org.uk/




The compelling need for effective treatments for RTT, coupled with
the availability of good mouse models, is fuelling interest in translational
studies aimed at identifying potential new therapeutics. However, given
the substantial financial costs and high expectations of clinical trials,
it is incumbent upon the RTT research community to rigorously validate
models, outcome measures and study designs (see Table 3) that will
generate robust and reproducible preclinical findings with clear
relevance to the human disease. The NIH, as well as private Rett
syndrome funding organizations (IRSF and RSRT), recognize the added
demands that rigorous high-quality animal trials place on investigators,
especially in requesting independent replication of promising
therapeutic leads before moving forward. Current NIH research 




It is also imperative that the complexity of RTT pathophysiology is
taken fully into account in the design of preclinical studies. This includes
the recognition that loss of MeCP2 function can have direct effects on
neuronal function (e.g. synaptic strength) and development (e.g.
neuronal cell growth), as well as indirect and cumulative effects on long-
term maturation, leading to distinct phenotypic consequences and
possibly requiring different treatment strategies. Similarly, it will be
important to determine in RTT individuals which specific features might
be reversible with pharmacological treatment alone (and at what
developmental age) and which might require more complex
interventions (e.g. pharmacotherapy combined with behavioral,
cognitive and/or speech therapies). Understanding this complexity will
be essential in selecting therapeutic end points and to understanding
how best to reach them.
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